JP2024510757A5 - - Google Patents

Info

Publication number
JP2024510757A5
JP2024510757A5 JP2023557027A JP2023557027A JP2024510757A5 JP 2024510757 A5 JP2024510757 A5 JP 2024510757A5 JP 2023557027 A JP2023557027 A JP 2023557027A JP 2023557027 A JP2023557027 A JP 2023557027A JP 2024510757 A5 JP2024510757 A5 JP 2024510757A5
Authority
JP
Japan
Prior art keywords
amino acid
necessary
virus
acid sequence
aibp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510757A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/020991 external-priority patent/WO2022198073A1/en
Publication of JP2024510757A publication Critical patent/JP2024510757A/ja
Publication of JP2024510757A5 publication Critical patent/JP2024510757A5/ja
Pending legal-status Critical Current

Links

JP2023557027A 2021-03-18 2022-03-18 炎症細胞または活性化細胞を標的とし、炎症性の状態および疼痛を処置するかまたは改善するための組成物および方法 Pending JP2024510757A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162714P 2021-03-18 2021-03-18
US63/162,714 2021-03-18
PCT/US2022/020991 WO2022198073A1 (en) 2021-03-18 2022-03-18 Compositions and methods for targeting inflammatory or arctivated cells and treating or ameliorating inflammatory conditions and pain

Publications (2)

Publication Number Publication Date
JP2024510757A JP2024510757A (ja) 2024-03-11
JP2024510757A5 true JP2024510757A5 (https=) 2025-04-04

Family

ID=83321214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557027A Pending JP2024510757A (ja) 2021-03-18 2022-03-18 炎症細胞または活性化細胞を標的とし、炎症性の状態および疼痛を処置するかまたは改善するための組成物および方法

Country Status (10)

Country Link
US (1) US20240209341A1 (https=)
EP (1) EP4308233A4 (https=)
JP (1) JP2024510757A (https=)
KR (1) KR20230159847A (https=)
CN (1) CN117083381A (https=)
AU (1) AU2022238450A1 (https=)
CA (1) CA3212101A1 (https=)
IL (1) IL305955A (https=)
MX (1) MX2023010412A (https=)
WO (1) WO2022198073A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4203987A4 (en) * 2020-08-25 2024-10-16 The Regents of The University of California COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR NEUROINFLAMMATION
WO2025076208A1 (en) * 2023-10-03 2025-04-10 Raft Pharmaceuticals, Inc. Compositions and methods for treating pain disorders
WO2026006723A1 (en) * 2024-06-27 2026-01-02 Anand Rene Reagents and methods for treating headache and migraine pain and co-morbidities thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8513702D0 (en) 1985-05-30 1985-07-03 Gill S S Expansible trocar
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5874268A (en) 1996-09-23 1999-02-23 Duke University Method of introducing exogenous compounds into cells by electroporation and apparatus for same
SE9704076D0 (sv) 1997-11-06 1997-11-06 Holdingbolaget Vid Goeteborgs Method for permeabilisation of cell structures and use thereof
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20030181366A1 (en) * 2002-03-21 2003-09-25 Yan Luo Peptide inhibitors of Akt and uses thereof
US7343205B1 (en) 2002-08-20 2008-03-11 Boston Scientific Neuromodulation Corp. System and method for insertion of a device into the brain
ES2581781T3 (es) 2002-09-24 2016-09-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Método por imágenes para administración mejorada por convección de agentes terapéuticos
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
US20040151766A1 (en) 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005063156A1 (en) 2003-12-22 2005-07-14 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
JP3903061B2 (ja) 2003-12-24 2007-04-11 株式会社Ｌｔｔバイオファーマ 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
WO2006014035A1 (en) 2004-08-06 2006-02-09 Biospectrum, Inc. Multiple layered liposome and preparation method thereof
WO2006044986A1 (en) 2004-10-18 2006-04-27 Nitto Denko Corporation Intracellular peptide delivery
US20060129126A1 (en) 2004-11-19 2006-06-15 Kaplitt Michael G Infusion device and method for infusing material into the brain of a patient
CN101267805A (zh) 2005-07-27 2008-09-17 普洛体维生物治疗公司 制造脂质体的系统和方法
WO2008067183A1 (en) 2006-11-30 2008-06-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education A device for cell delivery into the brain or body
WO2008070769A1 (en) 2006-12-06 2008-06-12 Medtronic, Inc. Intrathecal catheter
US10364275B2 (en) * 2013-05-27 2019-07-30 The Regents Of The University Of California Methods for treating inflammatory responses or diseases caused by inflammation using ApoA-I binding protein (APOA1BP)
ES2883417T3 (es) * 2015-12-10 2021-12-07 Univ California Composiciones para su uso en el tratamiento o mejora de neuroinflamación, neurodegeneración, dolor neuropático y migraña

Similar Documents

Publication Publication Date Title
JP2024510757A5 (https=)
Watson et al. Surfactant proteins A and D: trimerized innate immunity proteins with an affinity for viral fusion proteins
ES2685611T3 (es) Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo
BR112019017697A2 (pt) vacinas contra influenza baseadas em vetores de vírus adenoassociado (aav)
Griffiths et al. The regulation of the CNS innate immune response is vital for the restoration of tissue homeostasis (repair) after acute brain injury: a brief review
US12428445B2 (en) Mini-nucleosome core proteins and use in nucleic acid delivery
RU2018143411A (ru) Лечение комплемент-опосредуемых расстройств
JP2023551903A5 (https=)
WO2018057916A1 (en) Novel humanized anti-ebola antibodies useful in preventing ebola infections
US20230062096A1 (en) Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with dnase1 and/or dnase1l3 deficiency
JP2020533968A (ja) 組換えアデノ随伴ベクター
TW202532642A (zh) 使用由人類神經或膠細胞產生的重組人類艾杜糖醛酸鹽 (iduronate)-2-硫酸酯酶 (ids) 之黏多醣病ii之治療
EP4081227B1 (en) Suppression of interleukin-17 production and inhibition of th17 cell generation by fibroblasts and products thereof
White et al. Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells
US20230372434A1 (en) Method of treating fibrosis with a combination therapy
TW202214849A (zh) 可溶性enpp1蛋白質及其用途
US12274757B2 (en) Recombinant adeno-associated viruses encoding serpin peptides and uses thereof
WO2024229151A2 (en) Multimeric coronavirus binding molecules and uses thereof
JP2024532426A (ja) エイズウイルス感染の遺伝子治療用の遺伝子配列構築体
US12617826B2 (en) CLEC2 fusion protein and uses thereof
US20230226158A1 (en) Compositions and methods for treating and/or preventing coagulopathy and/or sepsis in patients suffering from bacterial and/or viral infections
US20230365640A1 (en) Clec2 fusion protein and uses thereof
HK40091668A (zh) 用於治疗和/或预防患有细菌和/或病毒感染的患者的凝血病和/或脓毒症的组合物和方法
WO2025196087A1 (en) Targeting tissues in the cns
WO2025061682A1 (en) Adenoviral targeting of dendritic cells